Home | Articles
Published on:
Indian Journal of Pharmaceutical Education and Research, 2019; 54(1):xx-xx
Review Article | doi:10.5530/ijper.54.1.x

Treatment of Osteoporosis: Current Scenario from a Research Perspective


Authors and affiliation (s):

Pooja Umesh Pherwani1,2, Sadhana Sathaye2,*

1Bharati Vidyapeeth’s College of Pharmacy, Sector 8, CBD Belapur, Navi Mumbai, Maharashtra, INDIA.

2Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology (ICT), Nathalal Parekh Marg, Matunga, Mumbai, Maharashtra, INDIA.

Abstract:

Osteoporosis is a condition of compromised bone quality and bone density increasing the chances of fracture. In osteoporotic bone, there is a mismatch between bone formation and resorption. The high probability in both women (33.33%) and males (20%) over the age of 50 worldwide to suffer a fracture draws attention to the importance of treatment of osteoporosis. The benefits of using bisphosphonates, the first line of therapy in osteoporosis lasts for 5 years. The other drugs are recommended for a still shorter time. The state of usage of current drugs is discussed. Two drugs Abaloparatide and Romosozumab have been recently approved. There is a better understanding of the means of communication amongst the different players in bone remodeling. These players involved in remodeling, are subjected to local and systemic influences. This increased understanding of physiology led to molecules being investigated which acts on newer targets such as Cathepsin K, ɑvβ3 integrin, chloride channel 7, tryptophan hydroxylase 1, Src, calcium-sensing receptor. Also, a bone anabolic effect for certain drugs belonging to different therapeutic classes such as statins, nitrates, thiazides, beta-blockers has been noted. However, for these drugs, further studies regarding the dose and frequency of drug administration and the effectiveness in the prevention of fractures along with safety profiles are needed. The drugs acting on new targets and new uses of old drugs hold hope to increase our arsenal against osteoporosis and thus preventing the mortality and debility due to fractures.

Key words: Abaloparatide, Romosozumab, Cathepsin K, Chloride channel 7, ɑvβ3 integrin.

 

Articles in PDF, ePUB and Full text are attached to this page. In order to download, print or access these formats you must be logged in.
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
4 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.




 

Impact Factor

IJPER - An Official Publication of Association of Pharmaceutical Teachers of India is pleased to announce continued growth in the 2019 Release of Journal Citation Reports (source: 2018 Web of Science Data).

 

Impact Factor® as reported in the 2018 Journal Citation Reports® (Clarivate Analytics, 2019): 0.425

User login

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
10 + 10 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmaceutical Education and Research (IJPER) [ISSN-0019-5464] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 1967.

DOI HISTORY

IJPER uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2013 are being assigned DOIs for its permanent URLs